Overview

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation

Status:
Not yet recruiting

Trial end date:
2023-12-30

Target enrollment:

Participant gender:

Summary

Evaluate the efficacy，safety and pharmacokinetics of HLX208 in advanced non-small cell lung cancer patients with BRAF V600 mutation

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Henlius Biotech